Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue SUPPL. 1, 2003, Pages 13-14

  Kuenen, Bart C ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; GEMCITABINE; SEMAXANIB;

ANGIOGENESIS; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; ENDOTHELIUM; FEASIBILITY STUDY; HUMAN; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK FACTOR; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; THROMBOSIS;

ANGIOGENESIS INHIBITORS; ENDOTHELIUM, VASCULAR; HUMANS; INDOLES; NEOPLASMS; PYRROLES; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 0344928503     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073281     Document Type: Conference Paper

References (8)

1. Kuenen BC, Tabernero J, Baselga J, et al: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Research 2003;9:1648-1655.
2. Itokawa T, Nokihara H, Nishioka Y, et al: Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 2002;1:295-302.
3. Mendel DB, Laird AD, Smolich BD, et al: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
4. Mendel DB, Schreck RE, West DC, et al: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000;6:4848-4858.
5. Smolich BD, Yuen HA, West KA, et al: The anti-angiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001;97:1413-1421.
6. Kuenen BC, Levi M, Meijers JC, et al: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002;22:1500-1555.
7. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667.
8. Kuenen BC, Levi M, Meijers JC, et al: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21:2192-2198.